Rating History for Ligand Pharma (LGND) by Barclays
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 9/25/2026 | Glen Santangelo | New Coverage | Overweight (N/A) |
345.00 (N/A) |
298.41 (295.54) |
-0.96% | Details |
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
| Date | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|
| 9/25/2026 | Glen Santangelo | New Coverage | Overweight (N/A) |
345.00 (N/A) |
298.41 (295.54) |
-0.96% | Details |
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||
![]() |
|||||||